These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 20051060)

  • 1. Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma.
    Smith J; Rock G
    Transfusion; 2010 Apr; 50(4):926-31. PubMed ID: 20051060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at -30 degrees C.
    Bihm DJ; Ettinger A; Buytaert-Hoefen KA; Hendrix BK; Maldonado-Codina G; Rock G; Giclas PC; Goodrich RP
    Vox Sang; 2010 Feb; 98(2):108-15. PubMed ID: 19719460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins.
    Hornsey VS; Drummond O; Morrison A; McMillan L; MacGregor IR; Prowse CV
    Transfusion; 2009 Oct; 49(10):2167-72. PubMed ID: 19555414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein stability of previously frozen plasma, riboflavin and UV light-treated, refrozen and stored for up to 2 years at -30 °C.
    Ettinger A; Miklauz MM; Hendrix BK; Bihm DJ; Maldonado-Codina G; Goodrich RP
    Transfus Apher Sci; 2011 Feb; 44(1):25-31. PubMed ID: 21251884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen.
    Osselaer JC; Debry C; Goffaux M; Pineau J; Calomme G; Dubuc E; Chatelain B; Vandendaele MC; Hsu J; Rheinschmidt M; Lin L
    Transfusion; 2008 Jan; 48(1):108-17. PubMed ID: 17900283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of proteins in riboflavin and UV light-treated FFP during 1 year of storage at -18°C.
    Ettinger A; Miklauz MM; Hendrix BK; Bihm DJ; Maldonado-Codina G; Goodrich RP
    Transfus Apher Sci; 2012 Feb; 46(1):15-8. PubMed ID: 22115607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on pathogen reduction technology for therapeutic plasma: an overview.
    Solheim BG; Seghatchian J
    Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Storage of thawed plasma for a liquid plasma bank: impact of temperature and methylene blue pathogen inactivation.
    Thiele T; Kellner S; Hron G; Wasner C; Nauck M; Zimmermann K; Wessel A; Warkentin TE; Greinacher A; Selleng K
    Transfusion; 2012 Mar; 52(3):529-36. PubMed ID: 21880044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effectiveness of riboflavin photochemical-mediated virus inactivation and changes in protein retention in fresh-frozen plasma treated using a flow-based treatment device.
    Zhu L; Pan J; Wei C; Wang H; Xiang R; Zhang J; Wang D
    Transfusion; 2015 Jan; 55(1):100-7. PubMed ID: 25070346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of cryoprecipitate from riboflavin and UV light-treated plasma.
    Ettinger A; Miklauz MM; Bihm DJ; Maldonado-Codina G; Goodrich RP
    Transfus Apher Sci; 2012 Apr; 46(2):153-8. PubMed ID: 22342281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
    Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
    Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogen-reduction systems for blood components: the current position and future trends.
    Seghatchian J; de Sousa G
    Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.
    Picker SM; Steisel A; Gathof BS
    Transfusion; 2008 Aug; 48(8):1685-92. PubMed ID: 18513255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
    Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
    Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers.
    Schlenke P; Hervig T; Isola H; Wiesel ML; Kientz D; Pinkoski L; Singh Y; Lin L; Corash L; Cazenave JP
    Transfusion; 2008 Apr; 48(4):697-705. PubMed ID: 18194378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma.
    Tonnetti L; Proctor MC; Reddy HL; Goodrich RP; Leiby DA
    Transfusion; 2010 May; 50(5):1019-27. PubMed ID: 20030791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study.
    Picker SM; Steisel A; Gathof BS
    Transfus Apher Sci; 2009 Apr; 40(2):79-85. PubMed ID: 19233725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma constituent integrity in pre-storage vs. post-storage riboflavin and UV-light treatment--a comparative study.
    Balint B; Jovicic-Gojkov D; Todorovic-Balint M; Subota V; Pavlovic M; Goodrich R
    Transfus Apher Sci; 2013 Dec; 49(3):434-9. PubMed ID: 23820430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation.
    Reddy HL; Dayan AD; Cavagnaro J; Gad S; Li J; Goodrich RP
    Transfus Med Rev; 2008 Apr; 22(2):133-53. PubMed ID: 18353253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.
    Picker SM; Oustianskaia L; Schneider V; Gathof BS
    Vox Sang; 2009 Jul; 97(1):26-33. PubMed ID: 19302416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.